View in EDS HTML Full Text PDF Full Text

The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments.

Saved in:
Bibliographic Details
Title: The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments.
Authors: Meijer AJM; Department of Pediatric Oncology, Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands., Li KH; British Columbia Children's Hospital Research Institute, Vancouver, British Columbia, Canada., Brooks B; Department of Audiology and Speech Pathology, British Columbia Children's Hospital, Vancouver, British Columbia, Canada.; School of Audiology and Speech Science, University of British Columbia, Vancouver, British Columbia, Canada., Clemens E; Department of Pediatric Oncology, Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Department of Pediatric Oncology, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, the Netherlands., Ross CJ; Pharmaceutical Outcomes Program, British Columbia Children's Hospital, Vancouver, British Columbia, Canada.; Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada., Rassekh SR; Division of Hematology, Oncology, and Bone Marrow Transplant, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Hoetink AE; Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Center Utrecht-Wilhelmina Children's Hospital, Utrecht, the Netherlands., van Grotel M; Department of Pediatric Oncology, Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands., van den Heuvel-Eibrink MM; Department of Pediatric Oncology, Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Department of Pediatric Oncology, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, the Netherlands., Carleton BC; British Columbia Children's Hospital Research Institute, Vancouver, British Columbia, Canada.; Pharmaceutical Outcomes Program, British Columbia Children's Hospital, Vancouver, British Columbia, Canada.; Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Source: Cancer [Cancer] 2022 Jan 01; Vol. 128 (1), pp. 169-179. Date of Electronic Publication: 2021 Sep 07.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 34490624
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Meijer+AJM%22">Meijer AJM</searchLink>; Department of Pediatric Oncology, Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Li+KH%22">Li KH</searchLink>; British Columbia Children's Hospital Research Institute, Vancouver, British Columbia, Canada.<br /><searchLink fieldCode="AU" term="%22Brooks+B%22">Brooks B</searchLink>; Department of Audiology and Speech Pathology, British Columbia Children's Hospital, Vancouver, British Columbia, Canada.; School of Audiology and Speech Science, University of British Columbia, Vancouver, British Columbia, Canada.<br /><searchLink fieldCode="AU" term="%22Clemens+E%22">Clemens E</searchLink>; Department of Pediatric Oncology, Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Department of Pediatric Oncology, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Ross+CJ%22">Ross CJ</searchLink>; Pharmaceutical Outcomes Program, British Columbia Children's Hospital, Vancouver, British Columbia, Canada.; Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.<br /><searchLink fieldCode="AU" term="%22Rassekh+SR%22">Rassekh SR</searchLink>; Division of Hematology, Oncology, and Bone Marrow Transplant, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.<br /><searchLink fieldCode="AU" term="%22Hoetink+AE%22">Hoetink AE</searchLink>; Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Center Utrecht-Wilhelmina Children's Hospital, Utrecht, the Netherlands.<br /><searchLink fieldCode="AU" term="%22van+Grotel+M%22">van Grotel M</searchLink>; Department of Pediatric Oncology, Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands.<br /><searchLink fieldCode="AU" term="%22van+den+Heuvel-Eibrink+MM%22">van den Heuvel-Eibrink MM</searchLink>; Department of Pediatric Oncology, Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Department of Pediatric Oncology, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Carleton+BC%22">Carleton BC</searchLink>; British Columbia Children's Hospital Research Institute, Vancouver, British Columbia, Canada.; Pharmaceutical Outcomes Program, British Columbia Children's Hospital, Vancouver, British Columbia, Canada.; Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220374236%22">Cancer</searchLink> [Cancer] 2022 Jan 01; Vol. 128 (1), pp. 169-179. <i>Date of Electronic Publication: </i>2021 Sep 07.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley%22">Wiley </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0374236 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1097-0142 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220008543X%22">0008543X </searchLink><i>NLM ISO Abbreviation: </i>Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34490624
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/cncr.33848
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 169
    Titles:
      – TitleFull: The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Meijer AJM
      – PersonEntity:
          Name:
            NameFull: Li KH
      – PersonEntity:
          Name:
            NameFull: Brooks B
      – PersonEntity:
          Name:
            NameFull: Clemens E
      – PersonEntity:
          Name:
            NameFull: Ross CJ
      – PersonEntity:
          Name:
            NameFull: Rassekh SR
      – PersonEntity:
          Name:
            NameFull: Hoetink AE
      – PersonEntity:
          Name:
            NameFull: van Grotel M
      – PersonEntity:
          Name:
            NameFull: van den Heuvel-Eibrink MM
      – PersonEntity:
          Name:
            NameFull: Carleton BC
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: 2022 Jan 01
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1097-0142
          Numbering:
            – Type: volume
              Value: 128
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Cancer
              Type: main
ResultId 1